Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 5, 2019

RedHill’s Talicia receives FDA approval for H pylori therapy

Israel-based RedHill Biopharma has secured the US Food and Drug Administration (FDA) approval for Talicia capsules to treat adults with Helicobacter pylori (H pylori) infection.

Israel-based RedHill Biopharma has secured the US Food and Drug Administration (FDA) approval for Talicia capsules to treat adults with Helicobacter pylori (H pylori) infection.

Talicia is a combination of antibiotics, amoxicillin and rifabutin, along with proton pump inhibitor (PPI), omeprazole.

H pylori bacteria infects more than 50% of the global population, including 35% in the US.

Talicia is intended to address the growing resistance of the bacteria to the commonly used antibiotics in current standard-of-care therapies such as clarithromycin-based treatments.

According to estimates, the resistance of H pylori to clarithromycin nearly doubled during 2009-2013.

FDA approval supports positive results from two Phase III studies enrolling H pylori-positive adults with epigastric pain or discomfort in the US.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Data from the Phase III confirmatory study revealed 84% eradication of H pylori infection when treated with RedHill’s drug versus 58% in the active comparator arm.

In participants with measurable blood levels of drug at day 13, response rates were 90.3% and 64.7% with Talicia and the active comparator, respectively.

Trial data did not show any resistance to rifabutin, a principal component of the drug. Furthermore, 1% of subjects on RedHill’s drug had adverse reaction-related treatment discontinuation.

RedHill Biopharma CEO Dror Ben-Asher said: “The FDA’s approval of Talicia demonstrates our unwavering dedication to patients suffering from gastrointestinal diseases.

“We are working to expand our sales force to approximately 140 representatives who will promote Talicia, Aemcolo and other gastrointestinal-focused products in our basket.”

RedHill expects to launch Talicia in the US in the first quarter of next year. The company noted that the drug’s Qualified Infectious Disease Product (QIDP) designation provides market exclusivity in the country for eight years.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU